View More Recent Stories
-
Biogen (BIIB) PT Lowered to $313 at Piper Sandler
-
Biogen: RBC says 'very likely' that Leqembi will be approved in Europe
-
RBC Capital Reiterates Outperform Rating on Biogen (BIIB), very likely Leqembi will be approved in Europe
-
Biogen (BIIB) trades lower after after Lilly's Alzheimer's drug is approved
-
Biogen (BIIB) Completes Acquisition of Human Immunology Biosciences
-
RBC Capital on Biogen (BIIB): 'We See An EU Approval In 3Q24 As Likely'
-
RBC Capital Reiterates Outperform Rating on Biogen (BIIB)
-
Biogen (BIIB) Announces TOFIDENCE Approved in the EU
-
Scotiabank Reiterates Sector Outperform Rating on Biogen (BIIB)
-
Eisai, Biogen (BIIB) announced FDA acceptance of sBLA for LEQEMBI IV maintenance dosing
